Skip to main navigation Skip to search Skip to main content

A Phase 3 Randomized, Open-Label, Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

Upstate Medical University

Project: Research

Project Details

StatusFinished
Effective start/end date05/29/24 → 05/28/26

Funding

  • BeiGene USA, Incorporated: $72,738.00